The Current Ratio as of November 2024 (TTM) for NexImmune, Inc. (NEXI) is 0.66

According to NexImmune, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 0.66. This represents a change of -43.69% compared to the average of 1.17 of the last 4 quarters.

NexImmune, Inc. (NEXI) Historical Current Ratio (quarterly & annually)

How has NEXI Current Ratio performed in the past?

The mean historical Current Ratio of NexImmune, Inc. over the last ten years is 4.12. The current 0.66 Current Ratio has changed 1.50% with respect to the historical average. Over the past ten years (40 quarters), NEXI's Current Ratio was at its highest in in the June 2021 quarter at 20.28. The Current Ratio was at its lowest in in the March 2020 quarter at 0.

NexImmune, Inc. (NEXI) Current Ratio by Quarter and Year

Discovering the peaks and valleys of NexImmune, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

NexImmune, Inc. (NEXI) Average Current Ratio

How has NEXI Current Ratio performed in the past?

The current Current Ratio of NexImmune, Inc. (NEXI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

NexImmune, Inc. (NEXI) Current Ratio vs. Peers

How is NEXI’s Current Ratio compared to its peers?

NexImmune, Inc.’s Current Ratio is greater than ZyVersa Therapeutics, Inc. (0.06), less than Palisade Bio, Inc. (4.31), less than Unicycive Therapeutics, Inc. (3.37), less than Apexigen, Inc. (0.82), less than Immix Biopharma, Inc. (7.00), less than TransCode Therapeutics, Inc. (1.25), less than Landos Biopharma, Inc. (4.43), less than Oncorus, Inc. (1.50), less than Xenetic Biosciences, Inc. (5.05), less than eFFECTOR Therapeutics, Inc. (1.03), less than Virios Therapeutics, Inc. (7.27), less than Zura Bio Limited (12.57), greater than Navidea Biopharmaceuticals, Inc. (0.56), greater than CNS Pharmaceuticals, Inc. (0.31), less than Sonnet BioTherapeutics Holdings, Inc. (1.65), less than Mereo BioPharma Group plc (6.07), less than Terns Pharmaceuticals, Inc. (21.02), less than PDS Biotechnology Corporation (3.84), less than Inozyme Pharma, Inc. (9.84), less than HOOKIPA Pharma Inc. (3.86),

Build a custom stock screener for NexImmune, Inc. (NEXI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like NexImmune, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

NexImmune, Inc. (NEXI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like NexImmune, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.